Tuberculosis still continues to exert its terrible toll on human kind. Worldwide, a person is newly infected with TB every second, and overall nearly two billion people have been exposed to TB bacterium. During the 1990s, bright hopes that the disease would be vanquished by 2025 were extinguished as a variety of medical and social factors helped TB surge back to its familiar position among major causes of death. In revised national tuberculosis control program, time tested and established Short Course Chemotherapy adopted with altered strategy, where drug doses are given on alternate days under supervision. Adverse Drug Reaction is one of major determining factors for treatment outcome. In parts of Eastern Europe, nearly half of all TB cases resist at least one first-line drug. With proper treatment, almost all cases of TB are curable. But proper treatment is not always easy to attain. Typically, a TB patient takes four different antibiotics for at least two months, then two drugs for four more months. Hitting TB germs with several drugs simultaneously lessens the chance that naturally occurring mutations in the bacteria will allow some to escape destruction. However, the drugs often cause unpleasant side effects and because of that everyone may not complete the full course of treatment. Here an attempt has been made to counteract ADR of Anti Koch’s Treatment by administering Rasayana compound which contains: Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia (willd.)), Ashwagandha (Withania somnifera (L.) Dunal), Yastimadhu (Glycyrrhiza glabra Linn.), Pippali (Piper longum Linn.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa (Falc.)), Haridra (Curcuma longa Linn.) and Kulinjan (Alpinia galangal Linn.).

Key words: Tuberculosis, Short Course Chemotherapy, Adverse Drug Reaction, Rasayana therapy